IMS Health warns against head-to-head trial of Avastin, Lucentis

05/13/2008 | Financial Times (free content)

A $16 million clinical trial comparing Avastin and Lucentis, Genentech's age-related macular degeneration drugs, may benefit payers seeking to minimize the role of drugmakers in clinical trials but could present a disincentive for firms, IMS Health warned on Tuesday. IMS said that although the study could lead to cheaper alternatives to treat AMD, it could also alter the rules of drug development and possibly undermine blockbuster treatments long before they lose patent protection.

View Full Article in:

Financial Times (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA